Recursion Pharmaceuticals, Inc. RXRX
3.88 USD +0.20 (+5.43%)
At closeNov 4, 2026, 7:56 PM EST
3.85 -0.03 -0.77%
After hours · Nov 4, 7:56 PM ET
3.72 Day range 4.01
2.84 52-week range 5.00
- YTD
- -5.13%
- 1 year
- -22.40%
Analyst view
Consensus: buy
Buy
Price target (mean) 7.32 +88.6% upside
Now 3.88
- Target (low)
- 4.00
- Target (mean)
- 7.32
- Target (high)
- 10.00
Ratings (0m) 7 3 buy · 4 hold · 0 sell
- Strong buy2
- Buy1
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.22311 | -0.25 – -0.20 | -0.21 | -6.2% | 15.76M | -55.7% | 6 |
| Next quarter | -0.19333 | -0.21 – -0.17 | -0.21 | +7.9% | 11.38M | +75.8% | 6 |
| Current year | -0.89333 | -0.91 – -0.88 | -1.44 | +38.0% | 40.48M | -45.8% | 3 |
| Next year | -0.8572 | -0.96321 – -0.68 | -0.89333 | +4.0% | 59.07M | +45.9% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Needham | Reiterated | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | Needham | Reiterated | Buy | Buy |
| Apr 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 26, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Feb 26, 2026 | Needham | Reiterated | Buy | Buy |
| Dec 17, 2025 | JP Morgan | Upgrade | Neutral | Overweight |
| Sep 11, 2025 | Needham | Reiterated | Buy | Buy |
| Jul 8, 2025 | Needham | Reiterated | Buy | Buy |
| Jun 16, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| May 6, 2025 | Needham | Maintained | Buy | Buy |
| Apr 10, 2025 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 8, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 28, 2025 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Feb 6, 2025 | Needham | Reiterated | Buy | Buy |
| Jan 8, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Dec 11, 2024 | Needham | Reiterated | Buy | Buy |
| Nov 20, 2024 | Needham | Reiterated | Buy | Buy |
| Nov 7, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 4, 2024 | Needham | Maintained | Buy | Buy |
| Sep 3, 2024 | Jefferies | Maintained | Hold | Hold |
| Sep 3, 2024 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Aug 9, 2024 | Needham | Maintained | Buy | Buy |
| Jul 11, 2024 | Keybanc | Maintained | Overweight | Overweight |
| Jun 25, 2024 | Needham | Reiterated | Buy | Buy |
| May 10, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 9, 2024 | Needham | Reiterated | Buy | Buy |
| Mar 4, 2024 | Keybanc | Maintained | Overweight | Overweight |
| Feb 28, 2024 | Needham | Maintained | Buy | Buy |
| Jan 26, 2024 | TD Cowen | Initiated | — | Market Perform |